Wednesday 21st December 2016 |
Text too small? |
Abano Healthcare, fending off a hostile takeover from its biggest shareholder, cut 3 cents from the independent valuation it commissioned to allow for executive incentive shares while confirming a 73 percent gain in first-half profit
Net profit after minorities rose to $5.9 million, or 27.48 cents per share, in the six months ended Nov. 30, from $3.4 million, or 16.14 cents, a year earlier, the Auckland-based company said in a statement. Revenue was confirmed at $116.8 million, an 8 percent gain.
Abano released a summary of its results earlier this month, on growth in its dental network, to underline the value of the business in the face of a partial takeover bid from Healthcare Partners, an entity owned by cornerstone shareholders Anya and Peter Hutson and James Reeves.
Healthcare Partners yesterday criticised Abano's independent adviser report as using some unrealistic assumptions which plumped up Abano's value. The target company today revised its valuation range to between $9.92 and $11.93, from $9.95 to $11.96, to reflect 45,860 restricted shares issued to management last year as part of a long-term incentive scheme. Independent valuer Grant Samuel advised that this doesn't affect its assessment of the merits of the offer, and Abano's board still recommends shareholders reject the offer.
"While the Healthcare Partners partial takeover offer has been disruptive, management continue to focus on delivering strong results and an ongoing improving performance," chief executive Richard Keys said.
Abano's board confirmed an interim dividend of 16 cents per share, paid on Jan. 23 to shareholders on the register on Jan. 11. Healthcare Partners' $10-a-share offer for 50.01 percent of the company doesn't include the dividend, meaning its effective bid is $9.84, and Abano again complained about Healthcare's refusal to allow the dividend reinvestment plan to operate.
The Hutsons and Reeves poured about 4.1 million shares, or 19 percent of Abano, into the Healthcare Partners entity, and if the bid is successful, they would seek changes to improve the company's performance by halting acquisitions in the medium term in order to reduce debt, while improving the dental practices' operations. They would also install three new directors.
Abano's shares last traded at $8.21, having gained 8.3 percent so far this year, outpacing the 3.8 percent on the S&P/NZX All Index over the same period. The stock is rated an average 'buy' based on two analyst recommendations compiled by Reuters, with a median price target of $10.
Today's results show the healthcare investor bought 13 dental practices in the period, taking its tally to 197 in New Zealand and Australia as at Nov. 30, and it's bought a further three this month.
"The company's acquisition strategy will continue to provide additional operational, scale, and synergy benefits for the dental group as it continues to expand," Abano said. "The board expects this positive result and growth trajectory to continue into the second half of the year."
The dental division, which accounts for the bulk of Abano's earnings, lifted revenue 7.8 percent to $108.4 million in the half, with operating profit up 27 percent to $11.9 million. The radiology diagnostics unit posted a 13 percent increase in revenue to $8.4 million, generating earnings of $807,000 compared to just $61,000 a year earlier.
BusinessDesk.co.nz
No comments yet
Second St John withdrawal of labour takes effect tomorrow with further strikes likely
Sanford Appoints Independent Director
CRP ADVISES CLOSURE OF SHARE OFFER TO EXISTING INVESTOR
Devon Funds Morning Note - 14 August 2024
OCR 5.25% - Monetary restraint tempered as inflation converges on target
Consumers still need due diligence as new deposit takers emerge.
Woolworths strike: staff asked to dress up in Disney costumes for a week on their own dollar
Turners Invests in Quashed Online Insurance Platform
PGW Reports on Challenging Year
Arvida Announces Executive Team Changes